

THAT WHICH IS CLAIMED:

1. A pharmaceutical formulation suitable for inhalation, said formulation comprising at least one pharmaceutically active medicament and lactose anhydrate.
2. The pharmaceutical formulation according to Claim 1, wherein said formulation exhibits a weight gain of at least 0.3 percent equilibrated 25°C and 40 percent RH.
3. The pharmaceutical formulation according to Claim 1, wherein said formulation comprises at least about 1% w/w of said lactose anhydrate.
4. The pharmaceutical formulation according to Claim 1, wherein said formulation is a dry powder formulation.
5. The pharmaceutical formulation according to Claim 1, wherein said formulation is an aerosol formulation.
6. The pharmaceutical formulation according to Claim 1, wherein said at least one medicament is selected from the group consisting of analgesics, anginal preparations, antiinfectives, antihistamines, anti-inflammatories, antitussives, bronchodilators, diuretics, anticholinergics, hormones, xanthines, therapeutic proteins and peptides, salts thereof, esters thereof, solvates thereof, and combinations thereof.
7. The pharmaceutical formulation according to Claim 1, wherein the at least one medicament comprises at least one beta agonist.
8. The pharmaceutical formulation according to Claim 7, wherein the at least one beta agonist is selected from the group consisting of salbutamol, terbutaline, salmeterol, bitolterol, formoterol, esters thereof, solvates thereof, salts thereof, and combinations thereof.

9. The pharmaceutical formulation according to Claim 7, wherein the at least one beta agonist comprises salmeterol xinafoate.
10. The pharmaceutical formulation according to Claim 7, wherein the at least one beta agonist comprises salbutamol sulphate.
11. The pharmaceutical formulation according to Claim 1, wherein the at least one medicament comprises at least one anti-inflammatory steroid.
12. The pharmaceutical formulation according to Claim 11, wherein the at least one anti-inflammatory steroid is selected from the group consisting of mometasone, beclomethasone, budesonide, fluticasone, dexamethasone, flunisolide, triamcinolone, esters thereof, solvates thereof, salts thereof, and combinations thereof.
13. The pharmaceutical formulation according to Claim 11, wherein the at least one anti-inflammatory steroid comprises fluticasone propionate.
14. The pharmaceutical formulation according to Claim 1, wherein the at least one medicament comprises at least one beta agonist and at least one anti-inflammatory steroid.
15. The pharmaceutical formulation according to Claim 14, wherein the at least one beta agonist comprises salmeterol xinafoate and the at least one anti-inflammatory steroid comprises fluticasone propionate.
16. The pharmaceutical formulation according to Claim 1, wherein the at least one medicament is selected from the group consisting of beclomethasone, fluticasone, flunisolide, budesonide, rofleponide, mometasone, triamcinolone, noscapine, albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, terbutaline, tiotropium, ipatropium, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, isoetharine, tulobuterol, (-)-4-amino-3,5-dichloro- α -[[[6-[2-

(2-pyridinyl)ethoxy]hexyl]methyl] benzenemethanol, esters thereof, solvates thereof, salts thereof, and combinations thereof.

17. The pharmaceutical formulation according to Claim 1, wherein the at least one medicament is selected from the group consisting of albuterol sulphate, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate, and combinations thereof.

18. The pharmaceutical formulation according to Claim 1, further comprising at least one additional excipient.

19. The pharmaceutical formulation according to Claim 1, wherein the lactose anhydrate comprises amorphous lactose.

20. A pharmaceutical formulation consisting essentially of at least one pharmaceutically active medicament and lactose anhydrate.

21. The pharmaceutical formulation according to Claim 20, wherein said formulation exhibits a weight gain of at least 0.3 percent equilibrated 25°C and 40 percent RH.

22. A method for treating a respiratory disorder in a mammal comprising administering a pharmaceutically effective amount of a pharmaceutical formulation according to Claim 1.

23. The method according to Claim 22, wherein the respiratory disorder is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection, upper respiratory tract disease, and combinations thereof.

24. The method according to Claim 22, wherein said formulation is a dry powder formulation.

25. The method according to Claim 22, wherein said formulation is present in an aerosol formulation.

26. The method according to Claim 22, wherein said at least one medicament is selected from the group consisting of analgesics, anigal preparations, antiinfectives, antihistamines, anti-inflammatories, antitussives, bronchodilators, diuretics, anticholinergics, hormones, xanthines, therapeutic proteins and peptides, salts thereof, esters thereof, solvates thereof, and combinations thereof.

27. The method according to Claim 22, wherein the at least one medicament comprises at least one beta agonist.

28. The method according to Claim 27, wherein the at least one beta agonist is selected from the group consisting of salbutamol, terbutaline, salmeterol, bitolterol, formoterol, esters thereof, solvates thereof, salts thereof, and combinations thereof.

29. The method according to Claim 27, wherein the at least one beta agonist comprises salmeterol xinafoate.

30. The method according to Claim 27, wherein the at least one beta agonist comprises salbutamol sulphate.

31. The method according to Claim 22, wherein the at least one medicament comprises at least one anti-inflammatory steroid.

32. The method according to Claim 31, wherein the at least one anti-inflammatory steroid is selected from the group consisting of mometasone, beclomethasone, budesonide, fluticasone, dexamethasone, flunisolide, triamcinolone, esters thereof, solvates thereof, salts thereof, and combinations thereof.

33. The method according to Claim 31, wherein the at least one anti-inflammatory steroid comprises fluticasone propionate.

34. The method according to Claim 22, wherein the at least one medicament comprises at least one beta agonist and at least one anti-inflammatory steroid.

35. The method according to Claim 34, wherein the at least one beta agonist comprises salmeterol xinafoate and the at least one anti-inflammatory steroid comprises fluticasone propionate.

36. The method according to Claim 22, wherein the at least one medicament is selected from the group consisting of beclomethasone, fluticasone, flunisolide, budesonide, rofleponide, mometasone, triamcinolone, noscapine, albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, terbutaline, tiotropium, ipatropium, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, isoetharine, tulobuterol, (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]methyl] benzenemethanol, esters thereof, solvates thereof, salts thereof, and combinations thereof.

37. The method according to Claim 22, wherein the at least one medicament is selected from the group consisting of albuterol sulphate, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate, and combinations thereof.

38. The method according to Claim 22, said formulation further comprising at least one additional excipient.

39. The method according to Claim 22, wherein the lactose comprise amorphous lactose.

40. An inhalation device comprising a pharmaceutical formulation

contained therein, said pharmaceutical formulation comprising at least one pharmaceutically active medicament and lactose anhydrate.

41. The inhalation device according to Claim 40, wherein said formulation includes at least 1%w/w lactose anhydrate, and wherein said formulation exhibits a weight gain of at least 0.3 percent when equilibrated at 25°C and 40 percent RH.

42. The inhalation device according to Claim 40, wherein said inhalation device is a dry powder inhaler.

43. The inhalation device according to Claim 42, wherein the dry powder inhaler is a Diskus® inhaler.

44. The inhalation device according to Claim 40, wherein said inhalation device is a metered dose inhaler.

45. The inhalation device according to Claim 40, wherein said at least one medicament is selected from the group consisting of analgesics, anginal preparations, antiinfectives, antihistamines, anti-inflammatories, antitussives, bronchodilators, diuretics, anticholinergics, hormones, xanthines, therapeutic proteins and peptides, salts thereof, esters thereof, solvates thereof, and combinations thereof.

46. The inhalation device according to Claim 40, wherein the at least one medicament comprises at least one beta agonist.

47. The inhalation device according to Claim 46, wherein the at least one beta agonist is selected from the group consisting of salbutamol, terbutaline, salmeterol, bitolterol, formoterol, esters thereof, solvates thereof, salts thereof, and combinations thereof.

48. The inhalation device according to Claim 46, wherein the at least one beta agonist comprises salmeterol xinafoate.

49. The inhalation device according to Claim 46, wherein the at least one beta agonist comprises salbutamol sulphate.

50. The inhalation device according to Claim 40, wherein the at least one medicament comprises at least one anti-inflammatory steroid.

51. The inhalation device according to Claim 50, wherein the at least one anti-inflammatory steroid is selected from the group consisting of mometasone, beclomethasone, budesonide, fluticasone, dexamethasone, flunisolide, triamcinolone, esters thereof, solvates thereof, salts thereof, and combinations thereof.

52. The inhalation device according to Claim 50, wherein the at least one anti-inflammatory steroid comprises fluticasone propionate.

53. The inhalation device according to Claim 40, wherein the at least one medicament comprises at least one beta agonist and at least one anti-inflammatory steroid.

54. The inhalation device according to Claim 53, wherein the at least one beta agonist comprises salmeterol xinafoate and the at least one anti-inflammatory steroid comprises fluticasone propionate.

55. The inhalation device according to Claim 40, wherein the at least one medicament is selected from the group consisting of beclomethasone, fluticasone, flunisolide, budesonide, rofleponide, mometasone, triamcinolone, noscapine, albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, terbutaline, tiotropium, ipatropium, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, isoetharine, tulobuterol, (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]methyl] benzenemethanol, esters thereof, solvates thereof, salts thereof, and combinations thereof.

56. The inhalation device to Claim 40, wherein the at least one medicament is selected from the group consisting of albuterol sulphate, salmeterol xinafoate, fluticasone propionate, beclomethasone dipropionate, and combinations thereof.

57. The inhalation device according to Claim 40, wherein said pharmaceutical formulation further comprises at least one additional excipient.